Caidya Announces Strategic Combination with Simbec-Orion

The combination brings together the strengths of both companies to provide broader support for innovative biopharma firms. With operations across Europe, the Americas, Asia-Pacific, and China, the combined organization offers strong clinical development expertise and global execution capabilities.

Simbec-Orion adds early-stage clinical pharmacology capabilities and strong expertise in later-stage oncology and rare disease trials. This allows the combined company to support drug developers from first-in-human studies in both healthy volunteers and patients through to late-stage clinical trials and regulatory approval.

Together, the two organizations can better manage complex international clinical programs while offering broader services, deeper scientific expertise, and a more seamless development process. Clients will continue to receive the responsive, accountable, and collaborative support expected from a specialist clinical CRO.

Read More:MDOTM Raises $27M in Growth Equity Funding Round

With operations across Europe and nearly 50 years of experience, Simbec-Orion has built a strong reputation for supporting innovative biopharma companies. The company specializes in clinical pharmacology, oncology and rare disease research, providing services from Phase I to Phase III clinical trials.

The combination also includes Simbec-Orion’s 48-bed Phase I clinical pharmacology unit, one of Europe’s leading early-stage research facilities. This gives drug developers a seamless path from first-in-human studies through regulatory approval while maintaining continuity, expertise, and accountability throughout the development process.

“We are thrilled to bring together the Simbec-Orion, and Caidya teams,” said Barbara Lopez Kunz, Chief Executive Officer of Caidya. “This strategic combination brings together complementary strengths to create a more complete development partner for innovators. By combining Simbec-Orion’s European presence and early-phase expertise with Caidya’s global platform, we can support sponsors from First in Human through registration while helping them thrive where development becomes most difficult: at the intersection of scientific innovation, operational complexity, and global clinical execution.

“We are pleased to be joining forces with Caidya – which shares so much of our common culture,” said Fabrice Chartier, Chief Executive Officer of Simbec-Orion. “Our combined organization creates a CRO that combines the intimacy of a specialist partner with the reach of a global development organization to meet the needs of modern drug development. Together, we will enhance our combined geographic footprint, benefiting Simbec-Orion with enhanced access to the U.S. and Asian markets, and Caidya with greater presence in Europe and in Phase I clinical pharmacology.

“Simbec-Orion has built a reputation for excellence in clinical research, particularly in navigating the complexities of early phase development and European regulatory environments,” said Dr. Lingshi Tan Executive Chairman of the Board at Caidya. “By integrating their expertise with Caidya’s global reach and deep therapeutic experience, we are uniquely positioned to support the growing trend of cross border biopharma innovation, particularly the dual direction flow of therapies among the US, Europe and Asia.”

“CBPE has been proud to support significant investment in people and the digital transformation of Simbec-Orion, enabling strong growth since 2019. We are confident that joining forces with Caidya represents the ideal next chapter for the business, its people, and its clients,” said Anand Jain, Partner at CBPE and Chairman of Simbec-Orion. “By combining aligned cultures with a more connected development model, sponsors gain a continuous path from First-in-Human through to registration without changing the experienced partner they trust.”

About Caidya

Caidya is a global contract research organization (CRO) that helps biopharma companies develop new medicines faster, and more efficiently. The company specializes in managing complex clinical trials, including studies in challenging disease areas, rare patient populations and multinational programs. Caidya works closely with biopharma companies to support the development of innovative therapies for patients with unmet medical needs around the world.

Read More:Deeptech Startup Digiclean Raises €2.5 Mn in Seed Round